Skip to main content

Drug Interactions between edoxaban and Torisel

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

temsirolimus edoxaban

Applies to: Torisel (temsirolimus) and edoxaban

MONITOR CLOSELY: According to the package labeling, patients receiving temsirolimus in combination with anticoagulation therapy may be at increased risk of developing intracerebral bleeding, including fatal outcomes. The mechanism of interaction has not been described.

MANAGEMENT: Patients receiving anticoagulants should be informed of the increased risk of developing intracerebral bleeding while on temsirolimus.

References

  1. "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories (2007):

Switch to consumer interaction data

Drug and food interactions

Moderate

temsirolimus food

Applies to: Torisel (temsirolimus)

GENERALLY AVOID: Coadministration of temsirolimus with grapefruit juice may increase the plasma concentrations of sirolimus, a major active metabolite of temsirolimus and known substrate of CYP450 3A4. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism by certain compounds present in grapefruits.

MANAGEMENT: Patients treated with temsirolimus should preferably avoid the consumption of grapefruit or grapefruit juice.

References

  1. "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories (2007):

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer